Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Renal Cell Carcinoma. Found 64 abstracts

no pagination
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2019 Oct 09;:101097ju0000000000000588.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA. Discrimination of Malignant and Normal Kidney Tissue with Short Wave Infra-Red Dispersive Raman Spectroscopy. Journal of biophotonics. 2018 Jun;11(6):e201700188.
Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA. Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy. Journal of biophotonics. 2018 Jun;11(6):e201700188.
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. Eur Urol. 2018 Sep;74(3):387-93.
Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20;35(6):668-80.
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Ito T, Derweesh IH, Ginzburg S, Abbosh PH, Raheem OA, Mirheydar H, Hamilton Z, Chen DY, Smaldone MC, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG. Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. J Urol. 2017 Jan;197(1):31-6.
Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma. Journal of translational medicine. 2017 Apr 06;15(1):72.   PMCID: PMC5383954
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016 Sep;2(9):1179-86.   PMCID: PMC5568541
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU international. 2015 Sep;116(3):351-7.
Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015 Apr;13(2):e93-100.
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biology & Therapy. 2015 May;16(5):743-9.   PMCID: 4623021
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Renal Cell Carcinoma

Renal Cell Carcinoma Kidney Neoplasms Male Female Middle Aged drug therapy therapeutic use Aged pathology administration & dosage 80 and over Aged Adult Pyrroles Indoles adverse effects Antineoplastic Agents Disease-Free Survival Nephrectomy mortality methods genetics surgery therapy Survival Rate Risk Factors diagnosis Neoplasm Metastasis Retrospective Studies Disease Progression Sunitinib Pyrimidines secondary Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Sulfonamides Monoclonal Antibodies Kidney cancer Oral Administration statistics & numerical data Double-Blind Method Proto-Oncogene Proteins c-met Niacinamide Renal cell carcinoma Phenylurea Compounds Tumor Biomarkers tissue diagnosis Carcinogenesis Organ Sparing Treatments Adjuvant Chemotherapy Angiogenesis Inhibitors Nivolumab analogs & derivatives Nephrons epidemiology antagonists & inhibitors Pyrazines Aspirin Infrared Rays metabolism metastatic renal cell carcinoma Immune checkpoint inhibitor Signal transducer and activator of transcription STAT Intention to Treat Analysis cytoreductive nephrectomy Age Factors Ros Survival Analysis Vascular endothelial growth factor receptor VEGFR Targeted therapy Reactive Oxygen Species blood piperlongumine Amino acids Ribonucleic acid RNA Renal cell carcinoma RCC systemic therapy Molecular Models Patient Readmission High-Volume Hospitals Local Neoplasm Recurrence Mitogen-activated protein kinase MAPK Intravenous Administration Hepatocyte growth factor HGF Metastatic renal cell carcinoma Classification Raman spectroscopy Treatment patterns Pazopanib Young Adult Registries Follow-Up Studies Biological Models Spectroscopy etiology Prospective Studies cytology Perioperative Period Cancer survival survival Nuclear factor kappaB NF-kB hemorrhage Blood Transfusion Case-Control Studies Extracellular signal-regulated kinase Erk United States Tryptophan carcinoma Sorafenib Raman nephrectomy nutritional status Tyrosine kinase inhibitors TKIs Surgical Blood Loss Dioxolanes economics Ipilimumab Quality of Life enzymology Histidine Drug Costs Biopsy Immunotherapy Monoclonal Antibodies-Humanized pharmacology Antiangiogenic Single-Blind Method Raman Spectrum Analysis c-Met Hypoalbuminemia standards clopidogrel Immunological Antineoplastic Agents Focal adhesion kinase FAK Signal Transduction Oral anticancer medications Programmed Cell Death 1 Receptor Axitinib Neoplasm Staging Kidney Antineoplastic agents Medical Oncology Factual Databases Mice Risk Assessment Platelet Aggregation Inhibitors Logistic Models aspirin prevention & control Low-Volume Hospitals Response Evaluation Criteria in Solid Tumors
Last updated on Friday, January 03, 2020